Firmonertinib misses pivotal endpoint as investigator and independent PFS results diverge
Firmonertinib misses the FURVENT Phase 3 PFS endpoint in EGFR exon 20 insertion NSCLC despite stronger response and investigator-assessed results.
Pharma & Biotech